Mevastatin (compactin or ML-236B) is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. This drug induces apoptosis and arrest of cancer cells in G1 phase. Therapeutic effects of mevastatin on serum level of lipoproteins and unbiquinone-10 in patients with familial hypercholesterolemia were investigated. However, that study was discontinued. In addition, mevastatin was investigated for the treatment of melanoma. It was suggested, that mevastatin was unlikely to prevent melanoma at standard doses. However, higher doses could have a role to play in adjuvant therapy by inhibiting growth and invasion of melanoma cells. Also was revealed, that mevastatin increased histone deacetylase inhibitor, LBH589-induced cell death in triple-negative breast cancer (TNBC) cells.

The carotenoids lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ) accumulate in the central retina, where they are collectively known as macular pigment (MP). Each of these three compounds exhibit a regional dominance, with MZ, Z, and L being the dominant carotenoids at the epicenter, mid-periphery, and periphery of the macula, respectively. Meso-zeaxanthin is formed directly in the retina from lutein. MZ has potent anti-inflammatory effect, which can be due to its down-regulated expression of various inflammatory mediator genes. Meso-zeaxanthin was also found to scavenge superoxide radicals, hydroxyl radicals. MZ is a part of formulation for MacuShield, which is now the UK’s most recommended eye supplement. Also exists experiments supporting that LMZ3 (meso-zeaxanthin, lutein, zeaxanthin) supplements may stabilize vision and improve the cavitation’s in patients with macular telangiectasia type 2.